Meet Daniel

Daniel was diagnosed with severe hemophilia A at 5 months. As a boy, he learned that having hemophilia didn't have to be awkward; that most people would treat him the same as anyone else. To further encourage Daniel to take control of his condition, his mother, Patricia, actively supported his desire to play sports. Daniel understands the challenges of transitioning into adulthood while living with hemophilia. His mission is to speak to young children and teenagers about how to deal with the challenges of growing up with hemophilia.

Please see full Prescribing Information.

Individual results may vary.

USA15HDM01429c
USA15HDM01429c
Play
Pause
Skip
Volume
Chapters
Transcript
References
Subtitles
Fullscreen

Meet Daniel

Chapters
Transcript
References

Daniel was diagnosed with severe hemophilia A at 5 months. As a boy, he learned that having hemophilia didn't have to be awkward; that most people would treat him the same as anyone else. To further encourage Daniel to take control of his condition, his mother, Patricia, actively supported his desire to play sports. Daniel understands the challenges of transitioning into adulthood while living with hemophilia. His mission is to speak to young children and teenagers about how to deal with the challenges of growing up with hemophilia.

Please see full Prescribing Information.

Individual results may vary.

Return to overview

Transcripts

Return to overview

References


Selected Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Indications and Usage

Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur.  If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.

Please click here for Prescribing Information.